Testing BHV-8000 as a Treatment for Early Parkinson's Disease
Tests BHV-8000 against placebo in adults with early Parkinson's disease.
Plain-language title generated from the registry record
Registry title: A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Key facts
- Where
- Amiens Cedex 1, Besançon, Bordeaux, Bron, Caen, Créteil Cedex, Dijon, Grenoble Cedex 9, Lille, Marseille Cedex 5, Montpellier Cedex 5, Nantes Cedex 1, Nice, Nîmes, Paris, Poitiers, Rennes Cedex 09 France, Rouen, Strasbourg Cedex 2, and Toulouse, FranceSee the 20 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
- Has a doctor told you that you have a different condition with similar signs, such as multiple system atrophy or progressive supranuclear palsy?
- How long ago were you diagnosed with Parkinson's disease?
- Which medicine do you take for Parkinson's disease now?
Source: NCT06976268, who can take part
Where in France
- Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceNot yet recruiting
- CHU BesançonBesançon, FranceNot yet recruiting
- Centre hospitalier Universitaire de BordeauxBordeaux, FranceNot yet recruiting
- Hospices Civils de Lyon - Hôpital Pierre WertheimerBron, FranceNot yet recruiting
- Caen University HospitalCaen, FranceNot yet recruiting
- CHU Henri MondorCréteil Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de DijonDijon, FranceNot yet recruiting
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceNot yet recruiting
- CHU De Lille, Hôpital Roger SalengroLille, FranceNot yet recruiting
- Hôpital de la TimoneMarseille Cedex 5, FranceNot yet recruiting
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceNot yet recruiting
- CHU de Nantes - Hôpital LaennecNantes Cedex 1, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NiceNice, FranceNot yet recruiting
- CHU Caremeau Service de NeurologieNîmes, FranceNot yet recruiting
- Institut Du Cerveau Et De La Moelle EpiniereParis, FranceNot yet recruiting
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranceNot yet recruiting
- Hôpital Pontchaillou-CHU RennesRennes Cedex 09 France, FranceNot yet recruiting
- CHU de Rouen - Hôpital Charles NicolleRouen, FranceNot yet recruiting
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranceNot yet recruiting
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Biohaven Therapeutics Ltd.
- Trial code
- NCT06976268EU 2025-521113-13-00
- Record updated
- 22 October 2026
- Original description
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.Read full original descriptionShow less
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
Inclusion: Male or female participants 40 to 80 years of age, inclusive, at the time of informed consent; Meet the diagnostic criteria for "Probable PD" as assessed on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator; Have a clinician-documented diagnosis of idiopathic PD with an onset within 2 years of the Screening Visit.
Exclusion: Treatment with PD medication(s); Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including, but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia; Diagnosis of clinically significant central nervous system (CNS) disease other than PD; Any other condition(s) that may compromise participant safety, interfere with study conduct, or jeopardize the potential proper interpretation of study results, in the opinion of the investigator; Participants who are current smokers (defined as smoking [in any form, e.g., tobacco smoke, electronic cigarettes, etc.] ).